Our research group has already demonstrated that the reactivator of mutant p53 APR-246 enhanced the cytotoxic response of olaparib in mutant p53 NSCLC cells, resulting in a strong induction of apoptosis [25]. The gene discussed is TP53; the disease is non-small cell lung carcinoma.